In development“Our lead microglia program initially targets pediatric leukodystrophies, a group of rare, genetically defined neurological disorders that primarily affect the white matter of the CNS.”
In development“HLH is a rare, life-threatening hyperinflammatory disease characterized by immune dysregulation leading to excessive cytokine release and rapid progression to multiorgan dysfunction.”
Sells it“Rare disease product portfolio for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia and endocrine diseases – select products include: the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla and Hympavzi.”
Latest 10-KFY2025Impairment / charge ·
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue$62.6BYoY −1.6%
Net income$7.8BYoY −3.2%
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue$16.6BYoY −0.4%
Net income$3.2BYoY −8.4%
Latest 8-KCEO/CFO change ·
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.
Supplies it“Our customers use our NGS products in research and in the development and commercialization of their own workflows, including cancer detection through liquid biopsy and MRD as well as rare disease.”
Latest 10-KFY2026Positive ·
AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.
Revenue$459.4MYoY +22.0%
Net income−$130.2MYoY −67.6%
Latest 10-QQ3 FY2026Legal / investigation ·
Synthetic biology and therapeutics demand drove growth, but commercial and infrastructure spending widened operating losses.